Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

720.18 -2.62 (-0.36%)

Streaming Delayed Price Updated: 11:55 AM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

58 59 Next >

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

November 27, 2024

From Glancy Prongay & Murray LLP

Via Business Wire

Regeneron Pharmaceuticals Unusual Options Activity ↗

November 26, 2024

Via Benzinga

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

November 26, 2024

From Law Offices of Howard G. Smith

Via Business Wire

Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking ↗

November 19, 2024

Via Benzinga

Peering Into Regeneron Pharmaceuticals's Recent Short Interest ↗

November 18, 2024

Via Benzinga

Check Out What Whales Are Doing With REGN ↗

November 15, 2024

Via Benzinga

28 Analysts Have This To Say About Regeneron Pharmaceuticals ↗

November 14, 2024

Via Benzinga

Not-So-Big Pharma ↗

November 16, 2024

Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration.

Via Talk Markets

FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease ↗

November 15, 2024

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a decision expected by April 2025.

Via Benzinga

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

November 15, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Top Growth Stocks to Buy on the Dip ↗

November 14, 2024

Their recent issues are nothing to fret over for investors focused on the long game.

Via The Motley Fool

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease ↗

November 13, 2024

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.

Via Benzinga

Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry ↗

November 06, 2024

Via Benzinga

This Is What Whales Are Betting On Regeneron Pharmaceuticals ↗

November 04, 2024

Via Benzinga

Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH

November 13, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Announces Investor Conference Presentations

November 11, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

3 Recession-Resistant Stocks: Low Beta, High Margins, Low Debt

November 06, 2024

Check out these three stocks with financial metrics showing recession resistance and underlying business dynamics to back them up.

Via MarketBeat

Is It Time to Buy October's Worst-Performing Nasdaq Stocks? ↗

November 06, 2024

Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.

Via The Motley Fool

Regeneron Earnings Top Views For Biotech Giant ↗

October 31, 2024

Shares of the biotech giant have been in a sharp slide.

Via Investor's Business Daily

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

November 06, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say ↗

November 05, 2024

Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market.

Via Benzinga

Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required ↗

November 04, 2024

A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks.

Via Talk Markets

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

November 04, 2024

From Glancy Prongay & Murray LLP

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

November 04, 2024

From Law Offices of Howard G. Smith

Via Business Wire

The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

November 01, 2024

From The Law Offices of Frank R. Cruz

Via Business Wire

Why Is Regeneron Pharmaceuticals Stock Trading Lower Today? ↗

October 31, 2024

Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance.

Via Benzinga

Regeneron Reports Third Quarter 2024 Financial and Operating Results

October 31, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗

November 01, 2024

The major indexes declined, but haven't fallen apart.

Via Investor's Business Daily

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗

October 30, 2024

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Via Benzinga

Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday? ↗

October 31, 2024

Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months.

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.